Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Incorrect conclusions about unpublished pharmaceutical research

James Karagianis
CMAJ November 04, 2014 186 (16) 1246-2146; DOI: https://doi.org/10.1503/cmaj.114-0079
James Karagianis
Associate Professor of Psychiatry, University of Toronto, Toronto, Ont., and Psychiatrist in Chief, Waypoint Centre for Mental Health Care, Penetanguishene, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In a CMAJ news article,1 David Juurlink states that “there is no obligation on a manufacturer to publish the results of a study,” and that he “only sees the evidence that the companies let come to light.”

Pharmaceutical companies should not be blamed automatically for the failure to publish an article once a study is complete. Often, these papers are submitted for publication and are rejected by peer-reviewed journals. There are a number of potential reasons why a journal may reject a paper. Peer reviewers may have a bias against a particular drug, company or the entire pharmaceutical industry. Reviewers may think that the quality of the research is inadequate or that there are problems with how the paper is written. In such situations, the paper is usually revised and resubmitted, either to the same journal or to a different one.

Many journals are motivated by impact factor which, from a business standpoint, is completely understandable. Impact factor is a measure of how many times a journal’s published articles are cited.2 This measure can dictate how good a journal is perceived to be and can lead to increased readership and revenue. This concern over impact factor may lead journal editors to reject a study if they believe that study will not increase their journal’s impact factor. I suggest that negative or failed studies are most likely to fall into this category. Thus, a negative study may go unpublished because of a journal’s business priorities and not because a pharmaceutical company is withholding data. Unfortunately, this gives the appearance that there is an overrepresentation of positive studies and an underrepresentation of negative studies when the literature is subsequently reviewed.

Any study done in the United States, including most clinical trials with Canadian sites, must be registered with www.clinicaltrials.gov. All pharmaceutical companies must post study results within a reasonable period of time following study completion. Also, some companies require researchers to post study results on public websites. Not adhering to these rules can result in huge financial penalties. Companies risk a decline in stock price if they are accused of not publishing results, and therefore they have much to lose from not publishing even negative studies.

Readers should not assume that non-publication in a journal automatically equates to the purposeful withholding of data.

References

  1. ↵
    1. Collier R
    . UK Parliament calls for sharing of all clinical trial data. CMAJ 2014;186: 176
    OpenUrlFREE Full Text
  2. ↵
    1. Hecht F,
    2. Hecht BK,
    3. Sandberg AA
    . The journal “impact factor”: a misnamed, misleading, misused measure. Cancer Genet Cytogenet 1998 Jul 15;104: 77–81.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (16)
CMAJ
Vol. 186, Issue 16
4 Nov 2014
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Incorrect conclusions about unpublished pharmaceutical research
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Incorrect conclusions about unpublished pharmaceutical research
James Karagianis
CMAJ Nov 2014, 186 (16) 1246-2146; DOI: 10.1503/cmaj.114-0079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Incorrect conclusions about unpublished pharmaceutical research
James Karagianis
CMAJ Nov 2014, 186 (16) 1246-2146; DOI: 10.1503/cmaj.114-0079
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Induction of labour
  • Google Scholar

More in this TOC Section

  • Hospital-at-home programs in Canada: challenges and pitfalls
  • Author response to “Pitfalls of analyzing perinatal outcomes by health care provider”
  • Pitfalls of analyzing perinatal outcomes by health care provider
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire